<DOC>
	<DOCNO>NCT02170012</DOCNO>
	<brief_summary>The purpose study healthy elderly people evaluate safety , toleration time course plasma concentration multiple oral dos PF-06743649- The pharmacodynamic activity PF-06743649 also assess .</brief_summary>
	<brief_title>A Study In Healthy Elderly People To Evaluate Safety , Toleration , Pharmacokinetics Pharmacodynamics Multiple Oral Doses Of PF-06743649</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subject age 65 85 year , inclusive . Ideally least 25 % subject enrol cohort 75 year age Screening . Subjects must healthy determine investigator base detailed medical history , full physical examination ( include blood pressure pulse rate measurement ) , 12lead ECG clinical laboratory test result . Subjects mild , chronic , stable disease stable medication may enrol deem medically prudent investigator . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Evidence personally sign date informed consent document indicate subject ( legally acceptable representative ) inform pertinent aspect study . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Any condition possibly affect drug absorption ( eg , gastrectomy ) . Evidence gout/hyperuricemia , measure sUA &gt; 8 mg/dL screening . Experienced episode nephrolithiasis ureterolithiasis .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Multiple dose</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>PK</keyword>
</DOC>